Article
Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non small cell lung cancers.
Molecular cancer therapeutics - 1 Oct 2007
Doody Jacqueline F, Wang Ying, Patel Sheetal N, Joynes Christopher, Lee Sui Ping, Gerlak Jason, Rolser Robin L, Li Yanxia, Steiner Philipp, Bassi Rajiv, Hicklin Dan J, Hadari Yaron R
Abstract excerpt
Mutations in the kinase domain of the epidermal growth factor receptor (EGFR) were identified in approximately 15% of all patients with non-small cell lung cancer (NSCLC). These mutations have been established as an indicator of superior response to gefitinib and erlotinib, small molecule inhibitors of the EGFR kinase domain. Whether these mutations would also render patients more susceptible to treatment with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.